TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2009

Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.

Alfonso Quintás-Cardama et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.